The safety of artemisinins during pregnancy: a pressing question
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increasing number of countries in sub-Saharan Africa are changing to artemisinins combination therapy (ACT) as first or second line treatment for malaria. There is an urgent need to assess the safety of these drugs in pregnant women who may be inadvertently exposed to or actively treated with ACTs. OBJECTIVES: To examine existing published evidence on the relationship between artemisinin compounds and adverse pregnancy outcomes and consider the published evidence with regard to the safety of these compounds when administered during pregnancy. METHODS: Studies on ACT use in pregnancy were identified via searches of MEDLINE, EMBASE, Cochrane and Current Contents databases. Data on study characteristics, maternal adverse events, pregnancy outcomes and infant follow up were extracted. RESULTS: Fourteen relevant studies (nine descriptive/case reports and five controlled trials) were identified. Numbers of participants in these studies ranged from six to 461. Overall there were reports on 945 women exposed to an artemisinin during pregnancy, 123 in the 1st trimester and 822 in 2nd or 3rd trimesters. The primary end points for these studies were drug efficacy and parasite clearance. Secondary endpoints were birth outcomes including low birth weight, pre-term birth, pregnancy loss, congenital anomalies and developmental milestones. While none of the studies found evidence for an association between the use of artemisinin compounds and increased risk of adverse pregnancy outcomes, none were of sufficient size to detect small differences in event rates that could be of public health importance. Heterogeneity between studies in the artemisinin and comparator drugs used, and in definitions of adverse pregnancy outcomes, limited any pooled analysis. CONCLUSION: The limited data available suggest that artemisinins are effective and unlikely to be cause of foetal loss or abnormalities, when used in late pregnancy. However, none of these studies had adequate power to rule out rare serious adverse events, even in 2nd and 3rd trimesters and there is not enough evidence to effectively assess the risk-benefit profile of artemisinin compounds for pregnant women particularly for 1st trimester exposure. Methodologically rigorous, larger studies and post-marketing pharmacovigilance are urgently required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The burden of malaria in pregnancy in malaria-endemic areas
Steketee, R., Nahlen, B., Parise, M., & Menendez, C. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.28 · Cited by 1,063
McGready, R., Cho, T., Keo, N. K., Thwai, K. L., Villegas, L., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Clinical Infectious Diseases · doi:10.1086/324349 · Cited by 178 · cited 3×
“TBB, 1992–2000 [16] Artesunate alone or with mefloquine; clindamycin atovaquone-proguanil; coartemether, artemether IM 461 (89%) No ADRs (pruritus) Maternal deaths (n = 2)* Abortions 4.”
Effects of Malaria during Pregnancy on Infant Mortality in an Area of Low Malaria Transmission
Luxemburger, C. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.5.459 · Cited by 178
McGready, R., Cho, T., Samuel, Villegas, L., Brockman, A., van Vugt, M., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90106-3 · Cited by 114 · cited 5×
“This was followed in 2001 by a report of a randomized trial of artesunate versus quinine plus clindamycin in 129 pregnant women [13].”
BackgroundMethodInfluentialMcGready, R., Ashley, E. A., Moo, E., Cho, T., Barends, M., Hutagalung, R., Looareesuwan, S., White, N. J., & Nosten, F. (2005) · The Journal of Infectious Diseases · doi:10.1086/432551 · Cited by 112 · cited 4×
“TBB, 2001–2003 [11] 1)Quinine n = 42 2) Artesunate atovaquone-proguanil (AAP) n = 39 81 (91%) 1 maternal death** Tinnitus (24%) more frequent in Q (p < 0.”
InfluentialMcGready, R., Brockman, A., Cho, T., Cho, D., van Vugt, M., Luxemburger, C., Chongsuphajaisiddhi, T., White, N. J., & Nosten, F. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90235-9 · Cited by 110
The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy
Deen, J. L., von Seidlein, L., Pinder, M., Walraven, G. E. L., & Greenwood, B. M. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90204-4 · Cited by 102
Self-citationMcGready, R., Stepniewska, K., Ward, S. A., Cho, T., Gilveray, G., Looareesuwan, S., White, N. J., & Nosten, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0118-y · Cited by 101 · cited 3×
“The second publication [20], focuses on the pharmacokinetics properties of the drugs in 24 of these women.”
BackgroundMcGready, R., Keo, N. K., Villegas, L., White, N. J., Looareesuwan, S., & Nosten, F. (2003) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(03)80040-8 · Cited by 64 · cited 3×
“TBB 1999–2001 [19] Artesunate+atovaquoneproguanil 27 (100%) Symptoms possible ADRs: Headache (42%); muscle/joint pain (30%); abdominal pain (42%); anorexia (40%); nausea (25%); vomiting (10%); rash (15%); dizziness (70%), tinnitus (24%); contraction (15%) and sleep disturbance (8%) Neonatal deaths (n = 1) Normal deliv…”
Cited by
Discovery, mechanisms of action and combination therapy of artemisinin
Cui, L., & Su, X.-Z. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.68 · Cited by 371
McGready, R., Lee, S., Wiladphaingern, J., Ashley, E., Rijken, M., Boel, M., Simpson, J., Paw, M., Pimanpanarak, M., Mu, O., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70339-5 · Cited by 228
McGready, R., Tan, S. O., Ashley, E. A., Pimanpanarak, M., Viladpai-nguen, J., Phaiphun, L., Wüstefeld, K., Barends, M., Laochan, N., Keereecharoen, L., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050253 · Cited by 136
“It took until 2003 for sufficient experience with artesunate treatment in pregnancy to accumulate [17–19], and for sufficient confidence to develop for ethical approval to be granted for a treatment protocol evaluating AL in pregnancy.”
BackgroundTarning, J., McGready, R., Lindegardh, N., Ashley, E. A., Pimanpanarak, M., Kamanikom, B., Annerberg, A., Day, N. P. J., Stepniewska, K., Singhasivanon, P., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00195-09 · Cited by 99
Singh, N. D., Kumar, S., & Daniell, H. (2016) · Plant Biotechnology Journal · doi:10.1111/pbi.12476 · Cited by 67
Metadata
- Authors
- Dellicour, S., Hall, S., Chandramohan, D., & Greenwood, B.
- Venue
- Malaria Journal
- Published
- 2007-02-14
- Volume
- 6
- Issue
- 1
- Pages
- 15-15
- ISSN
- 1475-2875 (ISSN-L)
- OpenAlex
- W2101953549
- Cited by
- 92
- References
- 9
- FWCI
- 14.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The safety of artemisinins during pregnancy: a pressing question. https://app.cochat.ai/papers/10.1186/1475-2875-6-15
- The paper
- Dellicour, S., Hall, S., Chandramohan, D., & Greenwood, B. (2007). The safety of artemisinins during pregnancy: a pressing question. Malaria Journal. https://doi.org/10.1186/1475-2875-6-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.